A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Study sponsor: Recursion Pharmaceuticals Inc. · RXRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-07Estimated
Enrollment · participants310Estimated
Source updated2026-11-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.